The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•16 April 2026•

1 min read

FDA Lifts Partial Clinical Hold on MacroGenics Cancer Study

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA has removed the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.

2MacroGenics plans to resume enrollment in the clinical study targeting gynecologic cancers.

MacroGenics, Inc. announced that the U.S. FDA has lifted the partial clinical hold on its Phase 2 LINNET study evaluating lorigerlimab. The clinical trial focuses on treating gynecologic cancers using the company's proprietary bispecific DART molecule technology. Following this regulatory clearance, MacroGenics plans to immediately resume patient enrollment in the study, addressing previous FDA concerns. This development marks a significant milestone for the clinical-stage biotech firm, effectively reducing R&D risks and stabilizing the development timeline. The company remains on track to provide a comprehensive program update by mid-2026. Market analysts view this move as a bullish signal for the stock, as it clears a major regulatory hurdle in the oncology pipeline.